French Maritime Pine Bark Extract

French maritime pine bark — scientific infographic poster

French maritime pine bark extract is a patented, standardized extract of the bark of the French maritime pine (Pinus pinaster ssp. atlantica) grown in the Les Landes de Gascogne forest of southwestern France. Roughly 65–75% of the extract is procyanidins (oligomeric proanthocyanidins, OPCs) — chains of catechin and epicatechin units — alongside polyphenolic monomers and phenolic acids. It is one of the most heavily researched botanical extracts in the world, with over 160 clinical trials and a consistent signature: potent free-radical scavenging, enhanced endothelial nitric oxide production, binding to and protection of collagen and elastin, and broad anti-inflammatory activity. The strongest evidence is in chronic venous insufficiency and edema, endothelial and blood-pressure support, skin photoprotection, and attention/cognition (including pediatric attention-deficit/hyperactivity disorder, ADHD).


Table of Contents

  1. What Pine Bark Extract Is
  2. Composition & Standardization
  3. Antioxidant & Vascular Mechanisms
  4. Circulation, Venous Insufficiency & Edema
  5. Blood Pressure & Endothelial Function
  6. Skin Health & Ultraviolet Photoprotection
  7. Cognition, Attention & Attention-Deficit/Hyperactivity Disorder
  8. Joint Health & Osteoarthritis
  9. Metabolic, Diabetic & Other Effects
  10. Pine Bark vs Grape Seed Extract
  11. Forms & Standardization Quality
  12. Doses Used in Studies
  13. Cautions and Contraindications
  14. Key Research Papers
  15. Connections
  16. Featured Videos

What Pine Bark Extract Is

Most of the clinical research on this extract used one specific water-based extract of the bark of the French maritime pine, Pinus pinaster, sold under a trademarked name; results may not transfer to other pine bark products. The trees are a single-species, single-origin monoculture grown without pesticides in the Les Landes coastal forest of Gascony, France. Because the source material, harvesting, and extraction are tightly controlled, every batch of the standardized extract has a defined polyphenol profile — which is the central reason its clinical literature is so reproducible compared with generic, unstandardized "pine bark" supplements.

It is important to be precise about the terminology, because it is a frequent point of confusion:

The history is notable: French chemist Jacques Masquelier identified the oligomeric proanthocyanidin (OPC) compounds in 1947, later turned to French maritime pine bark as his source, and patented a pine-bark extraction in 1951, from which the standardized, trademarked extract was eventually built — the fuller story is told in the dedicated History & Discovery article.

Back to Table of Contents

Composition & Standardization

The standardized extract is a complex but well-defined mixture of polyphenols. The USP monograph and the manufacturer's specification define it as containing approximately 65–75% procyanidins by weight, with the remainder consisting of polyphenolic monomers and phenolic acids. The main constituent classes are:

An important pharmacological point is that the large procyanidin polymers are not absorbed intact. After ingestion, gut microbiota metabolize them into smaller, absorbable metabolites — most notably δ-(3,4-dihydroxyphenyl)-γ-valerolactone (M1) and related valerolactones. These microbial metabolites, rather than the parent polymers, are thought to be responsible for much of the extract's in-vivo activity, which helps explain why effects can vary with an individual's gut flora and why benefits typically build over weeks rather than appearing immediately.

The standardization is what separates the trial extract from generic pine bark. Because the manufacturer controls a single-origin raw material and a fixed extraction, batch-to-batch polyphenol composition is consistent. Generic "pine bark extract" products vary widely in OPC content, source species, and processing — so clinical results from trials of the standardized extract cannot be assumed to transfer to an arbitrary pine bark supplement.

Back to Table of Contents

Antioxidant & Vascular Mechanisms

Pine bark extract acts through several interlocking mechanisms that together explain its vascular and anti-inflammatory effects:

The unifying theme is the blood-vessel wall. Whether the clinical target is leg swelling, blood pressure, retinal microcirculation, or skin, the common pathway is improved endothelial function, protected connective tissue, and reduced oxidative and inflammatory damage to the microvasculature.

Back to Table of Contents

Circulation, Venous Insufficiency & Edema

Chronic venous insufficiency (CVI) — the condition behind aching, heavy, swollen legs, varicose veins, and (in advanced cases) skin changes and ulcers — is the extract's flagship indication and the area with the most robust trial data.

In randomized controlled trials, the standardized extract at 150–360 mg/day for 4–8 weeks significantly reduced leg heaviness, swelling, and subcutaneous edema, and improved venous microcirculation measured by laser Doppler flowmetry and by the reduction in ankle/calf circumference. The 2020 Cochrane systematic review (an update of a 2012 review) gathered 27 randomized trials with 1,641 participants across 10 chronic conditions. For chronic venous insufficiency it found only two studies with 60 participants; for pain scores the data came from one study of 40 people, rated very low-certainty evidence, and the reviewers wrote that they “do not know” whether pine bark extract decreases pain scores. Risk of bias was unclear in 22 of the 27 trials, and the reviewers concluded that small sample sizes, few trials per condition, varied outcome measures and poor reporting mean “no definitive conclusions regarding the efficacy or safety of pine bark extract supplements are possible.”

In plain words: a long list of small trials is not the same as strong evidence. When each condition has only one or two small studies, and the reviewers cannot tell how reliably most of them were run or reported, the results cannot be relied on to hold up in larger trials, which is why the review reaches no firm verdict either way.

In a 2006 prospective, controlled study of 86 patients with severe CVI, the extract at 150 or 300 mg/day for 8 weeks was compared with micronized diosmin/hesperidin (a standard prescription venotonic in Europe) at 1,000 mg/day; the improvements in symptom scores, edema and skin microcirculation were significantly larger with the extract. The extract has also been studied for closely related microvascular problems:

The mechanistic story is coherent: the extract's collagen/elastin binding strengthens vessel walls, its reduction of capillary permeability limits fluid leakage, and its NO-mediated improvement of microcirculation enhances tissue perfusion and clearance — exactly the combination needed to address venous edema.

Back to Table of Contents

Blood Pressure & Endothelial Function

Through its eNOS-enhancing, NO-preserving action, French maritime pine bark extract produces modest reductions in blood pressure, most clearly in people with mild hypertension or endothelial dysfunction. Two 2020 meta-analyses disagree. One, of 12 clinical trials with 922 participants, found systolic blood pressure 3.22 mmHg and diastolic blood pressure 1.91 mmHg lower, with the diastolic effect seen only in trials longer than 12 weeks. The other, limited to 7 double-blind, placebo-controlled trials with 626 participants, found no significant change in systolic or diastolic blood pressure. A larger 2025 meta-analysis of 27 randomized trials with 1,685 participants found systolic blood pressure 2.26 mmHg and diastolic blood pressure 2.62 mmHg lower than in control groups.

Beyond office blood pressure, the extract has been shown to improve flow-mediated dilation (FMD) — the gold-standard ultrasound measure of endothelial health — in patients with coronary artery disease, and to allow reduction in the required dose of the calcium-channel blocker nifedipine in mild hypertensives. These effects place the extract alongside other endothelium-supporting antioxidants such as coenzyme Q10 (CoQ10) and dietary nitrate as a vascular-support agent rather than a primary antihypertensive drug.

Pooled results on blood fats disagree. A 2019 meta-analysis of 14 trials with 1,065 participants found no significant change in low-density lipoprotein (LDL) cholesterol, total cholesterol or triglycerides, and a small rise in high-density lipoprotein (HDL) cholesterol of 3.27 mg/dL. The 2025 meta-analysis of 27 trials with 1,685 participants found LDL cholesterol 5.07 mg/dL lower than in control groups and no significant change in HDL cholesterol, triglycerides or total cholesterol. Trials also report reductions in oxidized-LDL and in smoking-induced platelet aggregation. Oxidation of low-density lipoprotein particles is an early step in plaque formation; a related blood test is apolipoprotein B (ApoB).

Back to Table of Contents

Skin Health & Ultraviolet Photoprotection

Pine bark extract's combination of antioxidant capacity and collagen/elastin binding makes the skin a natural target, and the dermatological evidence is among its most interesting.

This positions pine bark extract alongside other skin-supportive antioxidants — vitamin C (a collagen cofactor), astaxanthin (a leading oral photoprotectant), and curcumin — in the "ingestible skincare" category.

Back to Table of Contents

Cognition, Attention & Attention-Deficit/Hyperactivity Disorder

French maritime pine bark extract has a sizeable literature in cognition and attention, much of it built on the same vascular logic: better cerebral microcirculation and reduced oxidative stress support neuronal function.

Attention-deficit/hyperactivity disorder (ADHD)

The most cited work is a 2006 randomized, double-blind, placebo-controlled trial in children with attention-deficit/hyperactivity disorder (Trebatická et al., European Child & Adolescent Psychiatry). One month of the extract at 1 mg/kg/day significantly reduced hyperactivity and improved attention, concentration, and visual-motor coordination compared with placebo, with symptoms relapsing about a month after the extract was stopped. A companion paper from the same group reported that the extract normalized oxidized-glutathione and total antioxidant status in these children, and a further analysis linked the clinical improvement to a reduction in urinary catecholamine excess. The trials are small and the effect modest, but the consistency of the oxidative-stress signal is notable.

A 2021 double-blind, placebo-controlled crossover trial from Taiwan gave 20 children with attention-deficit/hyperactivity disorder (17 boys and 3 girls, mean age 10) 25 or 50 mg of pine bark extract for 4 weeks and a placebo for 4 weeks, with a 2-week break in between. During the extract period, inattention and hyperactivity-impulsivity scores on a symptom rating scale (SNAP-IV) fell, and so did commission errors (wrong responses) on a computer attention test (Continuous Performance Test III). The ratio of reduced to oxidized glutathione in red blood cells rose and a blood marker of fat oxidation (TBARS) fell, but the attention-test change did not correlate with these antioxidant measures.

Cognition and mental performance in adults

Controlled and observational studies have reported that the extract improves sustained attention, working memory, decision-making, and mood in healthy students, professionals under occupational stress, and older adults, typically over 8–12 weeks at 100–150 mg/day. In a study of older normal subjects, the extract improved cognitive-function scores and reduced oxidative-stress markers over a year. Pilot work has also explored the extract in mild cognitive impairment and in the cognitive complaints that follow certain illnesses, generally pointing to small benefits tied to improved microcirculation and lower oxidative burden.

As with all of the extract's central nervous system (CNS) data, the trials are smaller and shorter than pharmaceutical-grade evidence, and the effect sizes are modest; the studies tested it as a low-risk adjunct rather than a primary treatment.

Back to Table of Contents

Joint Health & Osteoarthritis

Pine bark extract's NF-κB inhibition and matrix-metalloproteinase suppression give it a plausible role in osteoarthritis, where inflammatory enzymes degrade joint cartilage.

In a randomized, double-blind, placebo-controlled trial (Belcaro et al., Phytotherapy Research, 2008) of patients with knee osteoarthritis, 100 mg/day of the extract for 3 months reduced the overall Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, decreased pain and stiffness, improved physical function, and reduced reliance on nonsteroidal anti-inflammatory drug (NSAID) analgesics compared with placebo. A separate mechanistic study found that the extract taken before knee-replacement surgery lowered inflammatory markers (and matrix-metalloproteinase activity) measured directly in the removed cartilage and synovial fluid — biochemical confirmation that orally ingested pine bark metabolites reach and act within the joint.

The effect in trials was modest, and the extract has been studied as one part of broader anti-inflammatory joint approaches alongside agents such as curcumin and omega-3 fatty acids, not as a stand-alone cure.

Back to Table of Contents

Metabolic, Diabetic & Other Effects

Several additional areas have controlled or suggestive evidence:

Across these indications the recurring biological theme is the same vascular/anti-inflammatory mechanism applied to a different tissue bed.

Back to Table of Contents

Pine Bark vs Grape Seed Extract

French maritime pine bark extract and grape seed extract are the two best-known OPC supplements, and the comparison is worth understanding because they are frequently used interchangeably.

Back to Table of Contents

Forms & Standardization Quality

What this means for the evidence: Almost the entire clinical literature is on the one standardized extract; generic pine bark products vary in composition, and the studied benefits have not been shown to carry over to them.

Back to Table of Contents

Doses Used in Studies

Timing & expectations. The extract is water-soluble and was taken with or without food in trials. Because its active compounds are largely gut-microbial metabolites of the parent procyanidins, benefits build gradually — most trials assess outcomes at 4–12 weeks, not days. Some protocols split larger daily doses (for example 50 mg three times daily), aiming for steadier metabolite levels.

Back to Table of Contents

Cautions and Contraindications

French maritime pine bark extract has an excellent safety record across more than 160 clinical trials, with side effects typically no different from placebo. Important considerations:

Back to Table of Contents

Key Research Papers

The following are peer-reviewed clinical and review papers on French maritime pine bark extract, most of them on the standardized extract. Author names, titles, and journals are plain text; the linked year/volume/pages resolves to the DOI or PubMed record.

  1. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. International Journal of Clinical Pharmacology and Therapeutics. 2002;40(4):158–168. — doi:10.5414/cpp40158
  2. Gulati OP. Pycnogenol in chronic venous insufficiency and related venous disorders. Phytotherapy Research. 2014;28(3):348–362. — doi:10.1002/ptr.5019
  3. Robertson NU, Schoonees A, Brand A, Visser J. Pine bark (Pinus spp.) extract for treating chronic disorders. Cochrane Database of Systematic Reviews. 2020;9(9):CD008294. — PubMed PMID: 32990945
  4. Cesarone MR, Belcaro G, Rohdewald P, et al. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clinical and Applied Thrombosis/Hemostasis. 2006;12(2):205–212. — PubMed PMID: 16708123
  5. Liu X, Wei J, Tan F, et al. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with type 2 diabetes. Life Sciences. 2004;75(21):2505–2513. — doi:10.1016/j.lfs.2003.10.043
  6. Liu X, Wei J, Tan F, et al. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sciences. 2004;74(7):855–862. — doi:10.1016/j.lfs.2003.07.037
  7. Trebatická J, Kopasová S, Šuba J, et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. European Child & Adolescent Psychiatry. 2006;15(6):329–335. — doi:10.1007/s00787-006-0538-3
  8. Marini A, Grether-Beck S, Jaenicke T, et al. Pycnogenol effects on skin elasticity and hydration coincide with increased gene expressions of collagen type I and hyaluronic acid synthase. Skin Pharmacology and Physiology. 2012;25(2):86–92. — doi:10.1159/000335261
  9. Saliou C, Rimbach G, Moini H, et al. Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B–dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Free Radical Biology and Medicine. 2001;30(2):154–160. — doi:10.1016/s0891-5849(00)00445-7
  10. Belcaro G, Cesarone MR, Errichi S, et al. Treatment of osteoarthritis with Pycnogenol: the SVOS (San Valentino Osteoarthritis Study). Phytotherapy Research. 2008;22(4):518–523. — doi:10.1002/ptr.2376
  11. Liu X, Zhou HJ, Rohdewald P. French maritime pine bark extract Pycnogenol dose-dependently lowers glucose in type 2 diabetic patients. Diabetes Care. 2004;27(3):839. — doi:10.2337/diacare.27.3.839
  12. Hosseini S, Lee J, Sepulveda RT, et al. A randomized, double-blind, placebo-controlled, prospective, 16-week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutrition Research. 2001;21(9):1251–1260. — doi:10.1016/S0271-5317(01)00342-6
  13. Pourmasoumi M, Hadi A, Mohammadi H, Rouhani MH. Effect of pycnogenol supplementation on blood pressure: a systematic review and meta-analysis of clinical trials. Phytotherapy Research. 2020;34(1):67–76. — PubMed PMID: 31637782
  14. Fogacci F, Tocci G, Sahebkar A, et al. Effect of Pycnogenol on blood pressure: findings from a PRISMA compliant systematic review and meta-analysis of randomized, double-blind, placebo-controlled, clinical studies. Angiology. 2020;71(3):217–225. — PubMed PMID: 31763928
  15. Mohammadi S, Fulop T, Khalil A, et al. Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis. BMC Complementary Medicine and Therapies. 2025;25(1):71. — PubMed PMID: 39987124
  16. Hadi A, Pourmasoumi M, Mohammadi H, Javaheri A, Rouhani MH. The impact of pycnogenol supplementation on plasma lipids in humans: a systematic review and meta-analysis of clinical trials. Phytotherapy Research. 2019;33(2):276–287. — PubMed PMID: 30456865
  17. Hsu CD, Hsieh LH, Chen YL, et al. Complementary effects of pine bark extract supplementation on inattention, impulsivity, and antioxidative status in children with attention-deficit hyperactivity disorder: a double-blinded randomized placebo-controlled cross-over study. Phytotherapy Research. 2021;35(6):3226–3235. — PubMed PMID: 33559134

PubMed Topic Searches

  1. PubMed: standardized French maritime pine bark extract
  2. PubMed: standardized pine bark extract & chronic venous insufficiency
  3. PubMed: standardized pine bark extract, blood pressure & endothelial
  4. PubMed: standardized pine bark extract, skin & UV photoprotection
  5. PubMed: standardized pine bark extract, ADHD & attention
  6. PubMed: standardized pine bark extract, osteoarthritis & joint
  7. PubMed: standardized pine bark extract, diabetes & glucose
  8. PubMed: proanthocyanidins (pine bark & grape seed)

External Authoritative Resources

  1. NCCIH — Herbs and Supplements at a Glance
  2. MedlinePlus — Maritime Pine
  3. PubMed — All research on the standardized French maritime pine bark extract

Back to Table of Contents

Connections

Back to Table of Contents